Lovastatin Reduced Specific Brain Wave Activity
Researchers found the drug altered brain oscillation patterns in people with neurofibromatosis type 1.
Updated on Oct. 6, 2026 in Autism
In a study published October 6, 2026, researchers found that 60 mg doses of lovastatin reduced specific brain wave oscillations in fifteen individuals with neurofibromatosis type 1. The study utilized a randomized, triple-blind crossover design to examine neurological responses during face recognition tasks.
Why it matters
Neurofibromatosis type 1 involves dysregulation of the Ras/MAPK pathway and GABA system, which can affect cognitive processing. Understanding how medications like lovastatin modulate these brain oscillations may eventually offer new insight into neurological management for this population.
This randomized, triple-blind, placebo-controlled crossover study measured EEG responses in fifteen participants. Lovastatin modulated theta band power in the 5-6 Hz range, while no significant effects were observed in the alpha 8-11 Hz or beta 13-20 Hz bands.
The players
NIH
The National Institutes of Health oversees medical research and manages clinical trial databases like the one used for this study.
The details
Researchers used Morlet wavelets to compute event-related spectral perturbations from EEG data collected during emotional face recognition tasks. The medication targets systems influenced by the Ras/MAPK pathway and GABAergic signaling, which are known to be altered in neurofibromatosis type 1. By recording oscillatory responses, the team identified specific changes in theta band activity linked to the intervention.
Timeline
The findings were published on October 6, 2026.
Health Landscape
This study aligns with the broader research effort to map biological markers in neurofibromatosis type 1 to potential pharmacological interventions. It specifically evaluates the use of statins beyond their traditional role in lipid management by targeting neurobiological pathways.
These findings are preliminary and strictly represent the results of a small, experimental study on brain wave activity. Any questions regarding the use of statins or management of neurofibromatosis type 1 should be discussed directly with your physician.
The takeaway
This study demonstrates that specific brain wave activity in people with neurofibromatosis type 1 can be modulated by medication. Patients should monitor for updates in neurobiological research and consult with their neurologist about new diagnostic or treatment-related findings.
Further reading
For context on how neurological conditions are managed through research, visit Autism.
More information
Review the full NIH clinical trial registration details for this research study.
